Clevidipine for severe hypertension in acute heart failure: A VELOCITY trial analysis

Congestive Heart Failure

Volumn 16, Issue 2, 2010, Pages 55-59

  Frank Peacock IV, W ^a   Varon, Joseph ^b   Ebrahimi, Ramin ^c   Dunbar, Lala ^d   Pollack Jr, Charles V ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEVIDIPINE;

ACUTE HEART FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MALE; MUSCLE CRAMP; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CONFIDENCE INTERVALS; DIHYDROPYRIDINES; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951710905     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2009.00133.x     Document Type: Article

References (33)

1. Gheorghiade M, Zannad F, Sopko G. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005, 112(25):3958-3968.
2. Cleland JG, Swedberg K, Follath F. The euroheart failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003, 24(5):442-463.
3. Cotter G, Moshkovitz Y, Milovanov O. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002, 4(3):227-234.
4. Adams KF, Fonarow GC, Emerman CL. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005, 149(2):209-216.
5. Rosamond W, Flegal K, Friday G. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007, 115(5):e69-e171.
6. Peacock WF, Fonarow GC, Ander DS. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. Crit Pathw Cardiol. 2008, 7(2):83-86.
7. Gheorghiade M, De Luca L, Fonarow GC. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005, 96(6A):11G-17G.
8. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007, 12(2):87-90.
9. Gheorghiade M, Abraham WT, Albert NM. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006, 296(18):2217-2226.
10. Kirk JD, Costanzo MR. Managing patients with acute decompensated heart failure. Clinical Courier. 2006, 23:1-12.
11. Nieminen MS, Bohm M, Cowie MR. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J. 2005, 26(4):384-416.
12. Levy P, Compton S, Welch R. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007, 50(2):144-152.
13. Cotter G, Metzkor E, Kaluski E. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998, 351(9100):389-393.
14. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992, 21(6):669-674.
15. Bussmann WD, Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema. Am J Cardiol. 1978, 41(5):931-936.
16. Levy PD, Compton S, Welch R. Need For Mechanical Ventilation Is Reduced By the Use of High-Dose Nitroglycerin for Patients with Acute Cardiogenic Pulmonary Edema: results of an Open-Label Trial. Acad Emerg Med 2006, 13(5 suppl 1):S107.
17. Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev. 2007, 12(2):143-147.
18. Elkayam U, Janmohamed M, Habib M. Vasodilators in the management of acute heart failure. Crit Care Med. 2008, 36(suppl 1):S95-S105.
19. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005, 96(6A):32G-40G.
20. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol. 2005, 96(6A):59G-67G.
21. Levy JH, Mancao MY, Gitter R. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007, 105(4):918-925. table of contents
22. Kieler-Jensen N, Jolin-Mellgard A, Nordlander M, Ricksten SE. Coronary and sustemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after cardiac surgery. Acta Anaesthesiol Scand. 2000, 44:7.
23. Ericsson H, Fakt C, Jolin-Mellgard A. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999, 47(5):531-538.
24. Rodriguez G, Varon J. Clevidipine: a unique agent for the critical care practitioner. Crit Care Shock. 2006, 9(2):37-41.
25. Nordlander M, Sjoquist PO, Ericsson H. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004, 22(3):227-250. Fall
26. Ericsson H, Bredberg U, Eriksson U. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000, 92(4):993-1001.
27. Kieler-Jensen N, Jolin-Mellgard A, Nordlander M. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand. 2000, 44(2):186-193.
28. Pollack CV, Varon J, Garrison NA. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009, 53:329-338.
29. Singla N, Warltier DC, Gandhi SD. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008, 107(1):59-67.
30. Aronson S, Dyke CM, Stierer KA. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008, 107(4):1110-1121.
31. Aronson S, Dyke C, Stierer K. The ECLIPSE trials: comparative Studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008, 107:1110-1121.
32. Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care. 2003, 7(5):374-384.
33. Gilmore RM, Miller SJ, Stead LG. Severe hypertension in the emergency department patient. Emerg Med Clin North Am. 2005, 23(4):1141-1158.